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ABSTRACT 
A uniform definition of clinical suspicion of T-cell mediated rejection (TCMR) in liver 
transplantation (LT) is needed to homogenize clinical decisions, especially within 
randomized trials. The present multicentre study included a total of 470 primary LT 
recipients. The derivation cohort consisted of 142 patients who had clinically-driven 
liver biopsies at any time after LT. The external validation cohort included 328 patients 
who underwent protocol biopsies at day 7-10 after LT. The rates of moderate-severe 
histological TCMR were 33.8% in the derivation cohort and 43.6% in the validation 
cohort. Independent predictors (ie. risk factors) of moderate-severe TCMR in the 
derivation cohort were: serum bilirubin >4mg/dL (OR=5.83; p<0.001), rising bilirubin 
within the 4 days prior to liver biopsy (OR=4.57; p=0.003), and blood eosinophils count 
>0.1*109/L (OR=3.81; p=0.004). In the validation cohort, the number of risk factors 
was an independent predictor of moderate-severe TCMR (OR=1.74; p=0.001), after 
controlling for hepatitis C status. The number of risk factors paralleled the rates of 
moderate-severe TCMR in the derivation and validation cohorts (p<0.001 in both 
comparisons). In conclusion, increased serum bilirubin, rising bilirubin and eosinophilia 
are validated risk factors for moderate-severe histological TCMR, and could be used as 
objective criteria to select candidates for liver biopsy.  
 
KEYWORDS: Immunosuppression, liver biopsy, liver transplantation, T-cell mediated 
rejection. 
ABBREVIATIONS: IQR, interquartile range; LT, liver transplantation; TCMR, T-cell 
mediated rejection. 
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INTRODUCTION 
Acute T-cell mediated rejection (TCMR) is a frequent complication in liver 
transplantation (LT), and forms the primary efficacy endpoint in most randomized trials 
evaluating immunosuppressive drugs. The gold standard to diagnose and grade TCMR 
is histological assessment by using the Banff classification[1]. In the past, some 
institutions implemented protocol liver biopsies early after LT, and reported that up to 
80% of patients show histological features of TCMR. However, most of these episodes 
were mild and without any detrimental impact on graft survival[2-4]. Nowadays, 
protocol liver biopsies have been abandoned and only patients with clinical suspicion of 
rejection, which usually means raising transaminases otherwise unexplained, undergo a 
liver biopsy. However, transaminases are poor predictors of TCMR, and do not mirror 
its histological severity[2,5].  
The agreement among transplant physicians to define clinical suspicion of rejection and 
to advise biopsy after LT was evaluated in a study including 100 LT patients with 
protocol liver biopsies at day 7[6]. The concordance among clinicians was poor or very 
poor in 76% of comparisons (κ coefficient<0.40), and most importantly, the 
concordance between clinical suspicion of rejection and the histological assessment was 
very poor in all cases (κ coefficient <0.30). In randomized trials using biopsy-proven 
TCMR as primary efficacy endpoint, this heterogeneity in selecting candidates for liver 
biopsy may be translated into increased risk of bias, particularly in those with open label 
design and with multicenter involvement[7]. Therefore, if protocol liver biopsies are no 
longer to be used, a systematic approach to select candidates for liver biopsy according 
to their individual risk of moderate-severe TCMR is mandatory. This method should be 
accurate, reproducible, and based on routine parameters whenever possible. In addition, 
it should not include information regarding immunosuppression, so it can be 
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implemented in randomized trials without any confounding effect. Although previous 
studies have identified some clinical predictors of TCMR, such as younger age, low 
MELD score, underlying autoimmune liver disease, elevated blood eosinophils count 
and vitamin D deficiency [2,5,8,9], they are not sufficiently validated to guide clinical 
decisions. Biomarkers and immune function assays have been proposed, but again 
results are contradictory and they are not widely available[10-17].  
Within this clinical scenario, the aims of the present study were: 1) To identify 
independent predictors of histological TCMR among routine clinical and laboratory 
parameters, and 2) to design and validate an objective method to select patients at 
increased risk of TCMR after LT, and thus able to homogenize the selection of 
candidates for liver biopsy both in randomized trials and clinical practice.  
 
PATIENTS AND METHODS 
Study design, patients and variables 
This is a retrospective multicenter study including 470 adult primary LT patients who 
subsequently underwent a liver biopsy.  Patients were considered for inclusion if they 
had at least two determinations of complete blood count and liver tests (ie. 
transaminases, bilirubin and cholestatic parameters) within the 4 days prior to liver 
biopsy. Exclusion criteria were: multiorgan transplantation, HIV infection, ongoing 
vascular/biliary complications, treatment with boluses of steroids one month prior to 
liver biopsy and primary immunosuppression not based on tacrolimus. Although 
concomitant immunosuppressive drugs were allowed, patients with cyclosporine-based 
immunosuppression were excluded in order to increase homogeneity. Cyclosporine-
based protocols are seldom used nowadays given the increased risk of TCMR and graft 
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loss as compared with tacrolimus[18]. Included patients were divided in two cohorts: 1) 
A derivation cohort, which consisted in 142 patients transplanted from 2008 to 2014 in 
3 transplant institutions, and who had clinically-driven liver biopsies; 2) An external 
validation cohort including 328 consecutive patients transplanted in a single institution 
from 2000 to 2007 with protocol liver biopsies at day 7-10 after LT.  
All liver biopsies were systematically evaluated to diagnose and grade acute TCMR 
according to the Banff schema, which is based in the presence of mixed mainly portal 
inflammation, endothelitis and bile duct damage, and classifies TCMR as 
none/indeterminate, mild, moderate and severe[1]. Only moderate-severe histological 
TCMR was considered clinically significant for the present study, since mild TCMR 
does not require treatment in most cases and its prognostic impact is negligible[7]. In 
the derivation cohort, liver biopsies were indicated at any time after LT by the 
responsible transplant clinician in each center, either because of clinical suspicion of 
rejection, or under any other indication (mainly graft dysfunction or suspicion of 
hepatitis C recurrence). In the validation cohort, liver biopsies were scheduled between 
days 7-10 post-LT irrespective of graft function. A multicenter population with 
clinically-driven liver biopsies is “a priori” more heterogenous, whereas a cohort with 
protocol liver biopsies is expected to be more uniform and closer to the gold standard to 
diagnose TCMR. Therefore, the former population was used as a derivation cohort 
while the later served as validation. In both cohorts, liver biopsies were performed 
percutaneously, except for patients with abnormal coagulation parameters, in whom the 
transjugular approach was preferred.  
Risk factors of histological moderate-severe TCMR were screened among routine 
clinical and biochemical parameters including recipient age, pre-LT MELD score, 
gender, aetiology of liver disease, interval from LT to liver biopsy, mean tacrolimus 
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trough concentrations within the four days prior to liver biopsy, concomitant 
immunosuppressive drugs, transaminases (AST/ALT), cholestatic parameters 
(ALP/GGT), bilirubin, INR, serum creatinine and blood eosinophils count. The kinetics 
of liver tests within the 4 days prior to liver biopsy, calculated as the relative delta 
change within this period, were also analyzed as possible predictors of significant 
TCMR.    
Statistical analysis 
Statistical analysis was performed by using SPSS 22.0 (IBM, Chicago, USA) and 
SAS/STAT® software. Variables are displayed as frequency tables or mean ± standard 
deviations, except for asymmetric distributions which are presented as median and 
interquartile range (IQR). For continuous variables, optimal thresholds were obtained 
by using ROC curves. In the derivation cohort, the risk factors of moderate-severe 
histological TCMR were screened by using univariate analysis: Chi-square test was 
used for frequencies, Student's t test or ANOVA for continuous variables, and Mann–
Whitney's U or Kruskal–Wallis for asymmetric distributions. Multiple logistic 
regression was used to identify independent predictors of moderate-severe histological 
TCMR in the derivation cohort, and to explore their utility in the validation cohort. 
Those variables with p<0.20 in the univariate analysis were selected to enter the initial 
multivariate model. Not significant covariates were eliminated from the model in a 
backward stepwise process. The final model included independent predictors, 
significant interactions (if any) and confounding factors (both hepatitis C status and 
interval from LT to liver biopsy were potential confounding factors from the clinical 
point of view, and were controlled irrespective of their statistical behavior). A 
nomogram based on the multivariate logistic regression model was created to calculate 
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the individual risk of moderate-severe TCMR. Every hypothesis was two-tailed and 
considered significant if p<0.05. 
Sample size calculation 
The minimum sample size required was calculated by using EPIDAT® 3.1 (Xunta de 
Galicia). The following assumptions were made: 
- Expected negative predictive value (ability of the model to exclude moderate-severe 
histological TCMR): 80%-95% 
- Expected positive predictive value (ability of the model to predict moderate-severe 
histological TCMR): 55%-75% 
- Prevalence of moderate-severe TCMR in the included population: 35% 
- Statistical power: 80%; Alpha error: 5% 
Under these premises, the minimum sample size required was n=127 (n=142 after 
applying Yates’ correction). In the present study, the derivation cohort included 142 
patients and the validation cohort comprised 328 patients.  
 
RESULTS 
Descriptive study 
A descriptive evaluation of both derivation and validation cohorts is shown in table 1. 
Both cohorts were comparable in terms of age, pre-LT MELD score and gender. Since 
the derivation cohort consisted of clinically-driven liver biopsies at any time post-LT, 
the interval from LT to liver biopsy was longer and more heterogeneous among 
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patients, as compared with the validation cohort (33 days [IQR 13-161] vs 6 days [IQR 
5-8] respectively; p<0.001). Moderate-severe histological TCMR was present in 33.8% 
of patients in the derivation cohort and 43.6% of patients in the validation cohort. At the 
time of liver biopsy, mean tacrolimus trough concentrations were lower in the 
derivation cohort (8±3.9 ng/mL vs 9.2±5.5 ng/mL; p=0.019), but concomitant 
immunosuppressants were more frequent (62.7% vs 45.5%; p<0.001). Regarding 
biochemical parameters on the day of the liver biopsy, the derivation cohort was 
characterized by increased levels of AST, ALP and GGT, but lower eosinophils count, 
INR and creatinine, as compared with the validation cohort. In the derivation cohort, 
transaminases and cholestatic parameters were stable within the 4 days prior to liver 
biopsy (ie. relative delta change close to 100%). In the validation cohort, transaminases 
were decreasing (ie. relative delta change <100%) while cholestatic parameters were 
rising (ie. relative delta change >100%) within the same timeframe, as it would be 
expected at day 7-10 after LT.  
Risk factors of histological moderate-severe TCMR in the derivation cohort 
The histological evaluation of 142 included patients showed: indeterminate/none TCMR 
in 71 patients (50%), mild TCMR in 23 patients (16.2%), moderate TCMR in 29 
patients (20.4%) and severe histological TCMR in 19 patients (13.4%). Other 
significant histological findings among patients without TCMR were: hepatitis C 
recurrence (n=20; 28.1%), unspecific/minimal inflammatory changes (n=20; 28.1%), 
cholestasis (n=6; 8.4%), ischemia-reperfusion injury (n=4; 5.6%), 
steatosis/steatohepatitis (n=3; 4.2%), and venooclusive disease (n=3; 4.2%). Univariate 
analysis comparing patients with none/mild TCMR vs moderate-severe TCMR is shown 
in table 2. Patients with moderate-severe TCMR had a shorter interval between LT and 
liver biopsy (13 days [IQR 9-218] vs 50.5 days [IQR 17-160]; p=0.004), and less 
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frequent chronic hepatitis C as underlying liver disease (p=0.001). Mean tacrolimus 
trough concentrations within the 4 days prior to liver biopsy were marginally reduced in 
patients with moderate-severe TCMR as compared with none/mild TCMR (6.8 ng/mL 
vs 8.2 ng/mL; p=0.042). Patients with low tacrolimus exposure within the 4 days prior 
to liver biopsy, defined as trough concentrations <6 ng/mL within the first month or <4 
ng/mL thereafter, had increased rates of moderate-severe TCMR (51.4% vs 28%; 
p=0.011). Concomitant immunosuppressive drugs had no influence on the presence and 
grading of TCMR (p=0.46). Patients with moderate-severe TCMR were biochemically 
characterized by increased eosinophils count (p=0.001) and increased serum bilirubin 
(p<0.001) on the day of the liver biopsy, together with raising bilirubin (<0.001) and 
cholestatic parameters (p=0.001 for ALP and p=0.047 for GGT) within the 4 days prior 
to liver biopsy. Noteworthy, neither absolute transaminases on the day of the liver 
biopsy, nor delta relative change of transaminases within the 4 days prior to liver 
biopsy, were associated with increased risk of TCMR. The initial multivariate model 
included the following variables: pre-LT MELD, aetiology of liver disease, tacrolimus 
trough concentrations, absolute eosinophils count, ALT, bilirubin, and relative delta 
change of ALT, ALP, GGT, bilirubin and INR within the 4 days prior to liver biopsy. 
Hepatitis C status and interval from LT to liver biopsy were controlled as potential 
confounding factors. After excluding not significant covariates and exploring potential 
interactions, the final multivariate model is shown in table 3. Independent risk factors of 
moderate-severe TCMR were increased serum bilirubin on the day of the liver biopsy 
(OR=5.83; p<0.001), raising bilirubin within the 4 days prior to liver biopsy (OR=4.57; 
p=0.003), and increased absolute eosinophils count (OR=3.81; p=0.004). A nomogram 
based in such model was constructed to allow a simple calculation of the individual risk 
of moderate-severe TCMR (figure 1).  The optimal threshold for each risk factor was as 
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follows: serum bilirubin on the day of the liver biopsy > 4 mg/dL; relative delta 
bilirubin change within the 4 days prior to liver biopsy >100% (ie. any increase); 
Absolute eosinophils count on the day of the liver biopsy >0.1 x109. The combination of 
these risk factors had an area under ROC curve to predict moderate-severe histological 
TCMR of 0.81, which was superior to the area under ROC curve obtained from each 
component alone (ie. 0.74 for serum bilirubin, 0.70 for relative delta change of bilirubin 
and 0.66 for absolute eosinophils count). From the whole cohort (n=142), 30 patients 
did not have any risk factor (21.1%), 42 patients had one risk factor (29.6%), 47 patients 
had 2 risk factors (33.1%), and 23 patients fulfilled the 3 risk factors (16.2%). The 
number of risk factors paralleled the risk of moderate-severe TCMR: 0 risk factors=0%; 
1 risk factor=21.4%; 2 risk factors=42.6%; 3 risk factors=78.3%; p<0.001 (see figure 
2). 
Validation of risk factors of moderate-severe TCMR in a protocol biopsy population 
Among 328 patients with protocol liver biopsies at day 7-10 after LT, 55 patients 
(16.8%) had none/indeterminate TCMR, 130 patients (39.6%) had mild TCMR, 127 
patients (38.7%) had moderate TCMR, and 16 patients (4.9%) showed features of 
severe TCMR. The univariate analysis revealed that patients with moderate-severe 
histological TCMR had increased bilirubin (6.3 mg/dL [IQR 3.7-9.9] vs 4.5 mg/dL 
[IQR 2.3-8.7]; p=0.003) and increased absolute eosinophils count (0.38 x109 [IQR 0.23-
0.57] vs 0.51 x109 [IQR 0.30-0.77]; p=0.002) on the day of the protocol liver biopsy as 
compared with patients with no/mild TCMR. In addition, the delta relative increase of 
bilirubin within the 4 days prior to liver biopsy was greater among patients with 
moderate-severe TCMR (152% [IQR 95-253] vs 130% [IQR 78-221]; p=0.044). Some 
of the optimal thresholds for risk factors had to be adapted to the early phase after LT, 
which is characterized by a particular biochemical profile consisting in a progressive 
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improvement of the liver graft function and variable cholestasis related to ischemia-
reperfusion injury. The threshold remained unchanged for serum bilirubin on the day of 
the liver biopsy (ie. >4 mg/dL), but had to be increased for relative delta change of 
serum bilirubin within the 4 days prior to liver biopsy, which was placed at >130%, and 
for absolute eosinophils count on the day of the liver biopsy, which was >0.40 x109. 
According these thresholds, 40 patients (12.2%) had 0 risk factors, 97 patients (29.6%) 
had 1 risk factor, 114 patients (34.8%) had 2 risk factors and 77 patients (23.5%) had 3 
risk factors. The risk of moderate-severe histological TCMR increased with the number 
of risk factors: 27.5% with 0 risk factors, 35.1% with 1 risk factor, 41.2% with 2 risk 
factors, and 66.2% with 3 risk factors (p<0.001). The number of risk factors was an 
independent predictor of moderate-severe TCMR (OR 1.74 [95%CI 1.3-2.2]; p<0.001) 
after controlling for hepatitis C status (OR 0.53 [95%CI 0.30-0.92]; p<0.025).  
 
DISCUSSION 
A uniform definition for clinical suspicion of TCMR is paramount to guide clinical 
decisions and to tailor immunosuppression. In renal transplantation, serum creatinine 
and glomerular filtration rate mirror graft function, and are established markers of 
TCMR[19]. A similar utility was expected from transaminases in LT, but these do not 
provide information about liver function, and they are poor markers of TCMR[2]. The 
ambiguous meaning of rising transaminases after LT is responsible for the lack of 
agreement to diagnose TCMR among clinicians[6], and may introduce bias in 
randomized trials[7], thus hampering the path towards minimal immunosuppression and 
tolerance. In the present study, a simple and objective model based on routine 
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biochemical parameters was able to identify patients at increased risk of moderate-
severe histological TCMR to undergo a liver biopsy.  
Many studies have evaluated the role of non invasive biomarkers of TCMR among 
serum parameters of inflammation[11,17,20,21] or mediators of T-cell 
activation[10,22]. Unfortunately, none of these biomarkers has been implemented 
hitherto because of their complexity, lack of reproducibility/validation, inaccuracy or 
costs[15,23]. Regarding conventional liver tests, a standardized methodology to select 
candidates for liver biopsy after LT has been seldom attempted, and never fully 
accomplished. A recent systematic review of randomized controlled trials in LT 
published from 2007 to 2015, revealed that only 2 studies out of 30 (6.7%) used 
predefined criteria to select candidates for liver biopsy[7]. In one study, the indication 
of liver biopsy relied on subjective symptoms including fever, malaise, back or 
abdominal pain, tenderness or enlargement of the liver, or change in bile color, with or 
without rapid increase in transaminases (no thresholds defined)[24]. The second 
randomized trial considered patients at clinical suspicion of TCMR if they had rising 
transaminases among 3 consecutive test results (elevated >1.5 times above the baseline) 
or serum bilirubin elevated by >0.3 mg/dL from baseline[25]. Although less ambiguous, 
these latter criteria were based on opinion of experts and cut-offs were established 
arbitrarily. In large observational series, autoimmune liver disease, younger recipient 
age, eosinophilia and vitamin D deficiency, among others, were identified as risk factors 
for TCMR after LT, but it is unclear how to combine this information to obtain an 
individualized risk assessment in each patient [2,5,8,9]. A multivariate logistic 
regression model based on 100 LT patients with early protocol liver biopsies combined 
age, pre-LT MELD score, blood eosinophils count and tacrolimus trough concentrations 
prior to liver biopsy[6]. However, the model lacked of external validation, and was 
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hampered by its complex calculation. The methodology proposed in the present study to 
select candidates for liver biopsy is simple, rationale and objective. Although restricted 
to patients under tacrolimus-based immunosuppression, which currently form the vast 
majority among the LT population, the model is independent from trough 
concentrations and co-medications. Its components or risk factors are routine laboratory 
tests, dynamic and widely available. Their ability to mirror progressive graft 
dysfunction or spontaneous improvement is well established in clinical practice, but 
optimal thresholds were unknown, leading to a significant heterogeneity in selecting 
patients to liver biopsy. The present study provides cut-offs for bilirubin and blood 
eosinophils at different time-points after LT, thus allowing for a more objective and 
homogenous assessment. The potential utility of the model to monitor response to 
boluses of steroids was not analyzed in the present study and requires further 
investigations.     
The model based in risk factors was tested in two different clinical scenarios. The 
derivation cohort consisted in “a priori” more heterogeneous and multicenter population 
of patients with clinically-driven liver biopsies obtained at any time after LT. In this 
setting, lingered to current routine clinical practice, the presence of ≥2 risk factors had 
4-fold increased rates of moderate-severe TCMR. There were only 9 false negative 
patients, and all of them had one risk factor. Noteworthy, in absence of risk factors, no 
patient had moderate-severe TCMR. The model was then investigated within a larger 
population with protocol liver biopsies at day 7-10 after LT, which may be considered 
as more homogeneous and closer to the gold standard. External validation in larger 
cohorts is often desirable, as it allows to recalibrate the model to different 
circumstances, and to adapt thresholds[26]. The model based on risk factors was an 
independent predictor of moderate-severe TCMR in the protocol biopsy evaluation, but 
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negative predictive values were lower, and up to 1/3 of patients with 0 or 1 risk factor 
had moderate-severe TCMR. These unnoticed episodes of histological TCMR early 
after LT without graft dysfunction are thought to have limited prognostic relevance[27], 
and should not motivate the use of more intense immunosuppression[2,28]. Therefore, 
although the model would not select these patients for liver biopsy, as they are not 
within the current clinical scenario, this may not form a significant limitation.   
The present model is not a diagnostic test per se and it is not intended to waive liver 
biopsies. Empirical therapy of TCMR without histological confirmation should be 
strongly discouraged, even among patients with three risk factors. To the contrary, the 
applicability of the model relies on its capacity to homogenously select patients at “a 
priori” high risk of TCMR to undergo liver biopsy. This strategy would solve the 
current lack of agreement to define clinical suspicion of TCMR[6] and it may contribute 
to reduce variability both in randomized trials and in clinical practice. The derived 
nomogram would ease the clinical decision-making process at the bedside, and would 
allow for an informed decision to individually advise liver biopsy.     
The independent analysis of this model with much alike results in two contrasting 
clinical scenarios, as they are clinically-driven liver biopsies and early protocol 
biopsies, reinforced its external validity. Although serum bilirubin had identical 
thresholds for both, derivation and validation cohorts (ie.>4mg/dL), cutoffs of relative 
delta bilirubin and eosinophils count had to be adapted to the early phase after LT in the 
validation cohort. While any worsening of serum bilirubin was considered a risk factor 
in long-term stable patients, a more pronounced increase by >30% of serum bilirubin 
was required early after LT. In other words, a mild increase of serum bilirubin (<30%) 
does not translate into a significant risk of TCMR early after LT, but should be 
considered a risk factor if it occurs thereafter. On the other hand, blood eosinophils 
16 
 
count may be physiologically increased in the early post-operative phase. Although the 
underlying reasons are eluding and more likely multifactorial, this finding is not 
surprising given the well recognized role of eosinophils in tissue remodeling, 
inflammation and foreign-body reaction[29]. In the present study, blood eosinophilia 
was defined >0.4x109 early after LT, and >0.1 x109 thereafter.  
The potential influence of confounding factors should be taken into account. The risk of 
TCMR is highest within the first weeks after LT, and declines abruptly thereafter being 
extremely rare after the first year. On the other hand, recurrent hepatitis C has a later 
onset, but shares some histological features with TCMR, thus forming a challenging 
differential diagnosis even for experienced pathologists. In the present study, both 
factors -interval from LT to liver biopsy and hepatitis C status- were controlled in the 
multivariate analysis to avoid any confounding effect. Other potential confounders such 
as variable quality of liver biopsy specimens, lack of central pathology reading, or 
agreement among pathologists from different institutions could not be controlled and 
may have influenced negatively the accuracy of the model. Despite this, such a large 
and multicenter population with detailed biochemical and histological evaluation has no 
precedent in the literature and derived results should be used to improve the quality of 
randomized trials and to benefit clinical care. 
In summary, rising bilirubin over 4 mg/dL and increased blood eosinophils count 
defined as >0.4x109 within the first 10 days after LT, and >0.1x109 thereafter, are 
established risk factors of moderate-severe TCMR, whereas transaminases are not 
reliable. While awaiting novel biomarkers[23], the presence of more than one of these 
factors should motivate a liver biopsy to confirm the presence of TCMR and to establish 
its severity before starting targeted therapy. The implementation of this simple method 
would homogenize clinical practice, while decreasing the risk of bias in randomized 
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controlled trials evaluating immunosuppression and using TCMR as the primary 
efficacy endpoint.   
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FIGURE LEGENDS 
Figure 1. Nomogram to predict the individual risk of moderate-severe histological T-
cell mediated rejection (TCMR). For calculations, trace a vertical line from each 
predictor (1 to 4) to the first line labeled as “Points”. Then, sum points from each 
predictor and trace a vertical line from the “Total Points” axis to the “Risk of moderate-
severe TCMR” axis. 
Figure 2. Rates of moderate-severe histological T cell mediated rejection according to 
the number of risk factors identified (ie. increased serum bilirubin, rising bilirubin and 
increased absolute eosinophils count).  
 
